The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study
Year: 2018
Type: conference-abstract
Source: Blood
Institutions: Dana-Farber Cancer Institute, Flinders Medical Centre, St James's University Hospital, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Oncology Hematology Care, Columbia University Irving Medical Center, Semmelweis University, The University of Melbourne, Peter MacCallum Cancer Centre, St Vincent's Hospital Melbourne, Universität Ulm, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Verastem (United States), Comprehensive Cancer Center Vienna, Medical University of Vienna
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2905375175